Abstract
Protein therapeutics offer distinct advantages over other classes of drugs largely due to the high level of target specificity and generally low toxicity. Problems have, however, been encountered with some protein therapeutics inducing undesirable immune responses in patients. This immunogenicity can produce pleiotropic effects including the development of a high affinity B cell-mediated humoral response that is often directed against the therapeutic. Opinions are divided as to the principal causes of clinical immunogenicity and, as a result, this area has been the subject of much research. One thing that has emerged as a result of this intense activity is the development of pre-clinical models that can provide a level of prediction of the immunogenic potential of novel protein therapeutics before administration in man.
Keywords: Immunogenicity, deimmunization, T cell epitopes, protein therapeutics
Current Drug Safety
Title: Pre-Clinical Considerations in the Assessment of Immunogenicity for Protein Therapeutics
Volume: 5 Issue: 4
Author(s): Matthew P. Baker and Francis J. Carr
Affiliation:
Keywords: Immunogenicity, deimmunization, T cell epitopes, protein therapeutics
Abstract: Protein therapeutics offer distinct advantages over other classes of drugs largely due to the high level of target specificity and generally low toxicity. Problems have, however, been encountered with some protein therapeutics inducing undesirable immune responses in patients. This immunogenicity can produce pleiotropic effects including the development of a high affinity B cell-mediated humoral response that is often directed against the therapeutic. Opinions are divided as to the principal causes of clinical immunogenicity and, as a result, this area has been the subject of much research. One thing that has emerged as a result of this intense activity is the development of pre-clinical models that can provide a level of prediction of the immunogenic potential of novel protein therapeutics before administration in man.
Export Options
About this article
Cite this article as:
Baker P. Matthew and Carr J. Francis, Pre-Clinical Considerations in the Assessment of Immunogenicity for Protein Therapeutics, Current Drug Safety 2010; 5 (4) . https://dx.doi.org/10.2174/157488610792246000
DOI https://dx.doi.org/10.2174/157488610792246000 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Safe and Effective Delivery of Amphotericin B: A Survey of Patents
Recent Patents on Nanotechnology Interrelationships Among Gut Microbiota and Host: Paradigms, Role in Neurodegenerative Diseases and Future Prospects
CNS & Neurological Disorders - Drug Targets Glycine Rich P-loop Motif in Deoxyuridine Pyrophosphatase
Current Protein & Peptide Science Recent Advances in Nanoneurology for Drug Delivery to the Brain
Current Nanoscience Inflammation Theories in Psychotic Disorders: A Critical Review
Infectious Disorders - Drug Targets Voxel-Based Morphometry of the Human Brain: Methods and Applications
Current Medical Imaging Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry Expression of Signaling Molecules in Progressive Multifocal Leukoencephalopathy
Current HIV Research Matrix Metalloproteinase Dependent Cleavage of Cell Adhesion Molecules in the Pathogenesis of CNS Dysfunction with HIV and Methamphetamine
Current HIV Research Combining Oncolytic Virotherapy and Cytotoxic Therapies to Fight Cancer
Current Pharmaceutical Design Neural Progenitors and HIV-1- Associated Central Nervous System Disease in Adults and Children
Current HIV Research Association of Viruses in the Development of Cardiovascular Diseases
Current Pharmaceutical Design Unexpected Altered Specificity Is Responsible for St. Louis Encephalitis Virus Recombinant Protease Autoproteolysis
Protein & Peptide Letters Pharmacological Perspectives of Ayurvedic Herbs <i>viz. Alstonia scholaris</i> L., <i>Picrorhiza kurroa, Swertia chirata</i> and <i>Caesalpinia crista</i> Against COVID- 19: A Mini-Review
Mini-Reviews in Organic Chemistry Tau-Focused Immunotherapy for Alzheimers Disease and Related Tauopathies
Current Alzheimer Research Short- and Long-Term Survival of Nonsurgical Intensive Care Patients and its Relation to Diagnosis, Severity of Disease, Age and Comorbidities
Current Aging Science Exploring the Role of Nerve Growth Factor in Multiple Sclerosis: Implications in Myelin Repair
CNS & Neurological Disorders - Drug Targets Recent Advances in Synthesis of PAR Ligands as Therapeutic Strategy for Inflammatory Diseases
Mini-Reviews in Medicinal Chemistry Opiate Addiction Therapies and HIV-1 Tat: Interactive Effects on Glial [Ca<sup>2+</sup>]<sub>i</sub>, Oxyradical and Neuroinflammatory Chemokine Production and Correlative Neurotoxicity
Current HIV Research NS3 Helicases as Drug Targets
Current Chemical Biology